This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
==== MeSH E05.601.495 – immunoassay ==== MeSH E05.601.495.320 – immunoblotting MeSH E05.601.495.320.200 – blotting, western MeSH E05.601.495.350 – immunoenzyme techniques MeSH E05.601.495.350.170 – enzyme-linked immunosorbent assay MeSH E05.601.495.350.180 – enzyme multiplied immunoassay technique MeSH E05.601.495.380 – immunosorbent techniques MeSH E05.601.495.380.360 – enzyme-linked immunosorbent assay MeSH E05.601.495.380.810 – radioallergosorbent test MeSH E05.601.495.380.825 – radioimmunoprecipitation assay MeSH E05.601.495.380.830 – radioimmunosorbent test MeSH E05.601.495.639 – radioimmunoassay MeSH E05.601.495.639.405 – immunoradiometric assay MeSH E05.601.495.639.810 – radioallergosorbent test MeSH E05.601.495.639.825 – radioimmunoprecipitation assay MeSH E05.601.495.639.830 – radioimmunosorbent test
The 8.5 kg Mini- 11 and 25 kg Mini-12 can produce resolution mass spectra up to m/z 600, a range that makes it useful for studying metabolites, lipids, and other small molecules. The group also developed and incorporated a digital microfluidic platform to the MMS with the application to extract and quantify drugs in urine. Mini 12 can perform MS5 and analyze directly such complex samples as whole blood, untreated food, and environmental samples, without sample preparation or chromatographic separation.
Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful.
Sources: en.wikipedia.org
Another method of possible remediation for CEC is through the use of membrane bioreactors (MBRs) that act through mechanisms of sorption and biodegradation. Membrane bioreactors have shown results on being able to filter out certain solutes and chemicals from wastewater through methods of microfiltration, but due to the extremely small size of CEC, MBRs must rely on other mechanisms in order to ensure the removal of CEC. One mechanism that MBRs use to remove CEC from wastewater is sorption. Sorption of the CEC to sludge deposits in the MBR's system can allow the deposits to sit and be bombarded with water, causing the eventual biodegradation of CEC in the membrane. Sorption of a particular CEC can be even more efficient in the system if the CEC is hydrophobic, causing it to move from the wastewater to the sludge deposits more quickly.
Statins have a protective effect on blood vessels, and SSRIs such as fluoxetine may help symptoms, but the data is weak. PDE5 inhibitors, such as sildenafil and tadalafil, are used off-label to treat severe ischemia and ulcers in fingers and toes for people with secondary Raynaud's phenomenon; as of 2016, their role more generally in Raynaud's was not clear.
First, the inward current becomes primarily carried by sodium channels. Second, the delayed rectifier, a potassium channel current, increases to 3.5 times its initial strength. In order for the transition from a calcium-dependent action potential to a sodium-dependent action potential to proceed new channels must be added to the membrane. If Xenopus neurons are grown in an environment with RNA synthesis or protein synthesis inhibitors that transition is prevented. Even the electrical activity of the cell itself may play a role in channel expression. If action potentials in Xenopus myocytes are blocked, the typical increase in sodium and potassium current density is prevented or delayed. This maturation of electrical properties is seen across species. Xenopus sodium and potassium currents increase drastically after a neuron goes through its final phase of mitosis. The sodium current density of rat cortical neurons increases by 600% within the first two postnatal weeks.
Sources: en.wikipedia.org
=== Femarelle Rejuvenate === Femarelle Rejuvenate is intended for women in the perimenopausal stage and focuses on symptoms associated with hormonal fluctuations, including mood changes, tiredness, and changes affecting skin and hair. The formulation contains DT56a together with biotin and riboflavin (vitamin B2).
==== Dol ==== The dol (from the Latin word for pain, dolor) is a unit of measurement for pain. James D. Hardy, Herbert G. Wolff, and Helen Goodell of Cornell University proposed the unit based on their studies of pain during the 1940s and 1950s. They defined one dol to equal a just-noticeable difference in pain. The unit never came into widespread use and other methods are now used to assess the level of pain experienced by patients.
=== Caveats and considerations === Some SELEX reactions can generate probes that are dependent on primer binding regions for secondary structure formation. There are aptamer applications for which a short sequence, and thus primer truncation, is desirable. An advancement on the original method allows an RNA library to omit the constant primer regions, which can be difficult to remove after the selection process because they stabilize secondary structures that are unstable when formed by the random region alone.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.